Ruxience®

ACTIVE PRINCIPLE:
Rituximab

INDICATION:
B-cell chronic lymphocytic leukemia
Rheumatoid Arthritis
microscopic polyangiitis
Pemphigus

DATE:
26/04/2020

STATUS:
Authorized

MORE INFORMATION